Tumor DNA analysis aims to speed up enrollment in early cancer trials
NCT ID NCT04510766
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will analyze genetic material from stored tumor samples of 40 adults with advanced solid tumors or lymphoma. The goal is to see if molecular profiling can help identify more patients for early phase clinical trials. Researchers will track how many patients with a genetic profile are enrolled per year and what types of mutations are found.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help match more patients to early phase trials based on their tumor's genetic profile.
- What could go wrong
- This is a small, observational study that does not test a treatment. It may not lead to direct benefits for participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Oncology Institute of Southern Switzerland
RECRUITINGBellinzona, 6500, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can your own immune cells beat advanced cancer?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can engineered immune cells tackle brain lymphoma?